CN113244399A - 利用酪氨酸激酶抑制剂的组合物和方法 - Google Patents

利用酪氨酸激酶抑制剂的组合物和方法 Download PDF

Info

Publication number
CN113244399A
CN113244399A CN202110533185.2A CN202110533185A CN113244399A CN 113244399 A CN113244399 A CN 113244399A CN 202110533185 A CN202110533185 A CN 202110533185A CN 113244399 A CN113244399 A CN 113244399A
Authority
CN
China
Prior art keywords
tyrosine kinase
kinase inhibitor
dasatinib
mice
pzr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110533185.2A
Other languages
English (en)
Chinese (zh)
Inventor
A·班尼特
J-S·易
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN113244399A publication Critical patent/CN113244399A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202110533185.2A 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法 Pending CN113244399A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562107553P 2015-01-26 2015-01-26
US62/107,553 2015-01-26
US201562250052P 2015-11-03 2015-11-03
US62/250,052 2015-11-03
CN201680018121.6A CN107530298B (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680018121.6A Division CN107530298B (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Publications (1)

Publication Number Publication Date
CN113244399A true CN113244399A (zh) 2021-08-13

Family

ID=56544226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680018121.6A Active CN107530298B (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法
CN202110533185.2A Pending CN113244399A (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680018121.6A Active CN107530298B (zh) 2015-01-26 2016-01-26 利用酪氨酸激酶抑制剂的组合物和方法

Country Status (7)

Country Link
US (4) US10471059B2 (enExample)
EP (2) EP4653015A2 (enExample)
JP (4) JP6854766B2 (enExample)
CN (2) CN107530298B (enExample)
HK (1) HK1245678A1 (enExample)
MX (2) MX2017009643A (enExample)
WO (1) WO2016123086A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN106943595A (zh) * 2017-03-30 2017-07-14 福州大学 Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US20210196714A1 (en) * 2018-06-18 2021-07-01 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
JP7547356B2 (ja) * 2019-02-27 2024-09-09 アストラゼネカ・アクチエボラーグ Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法
WO2021119525A1 (en) * 2019-12-11 2021-06-17 Tiaki Therapeutics Inc. Shp1 and shp2 inhibitors and their methods of use
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20240075031A1 (en) * 2020-12-07 2024-03-07 Hht Foundation International, Inc. Method of treating hereditary hemorrhagic telangiectasia using pazopanib
WO2023127012A1 (ja) * 2021-12-27 2023-07-06 国立研究開発法人理化学研究所 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法
US20250195519A1 (en) * 2022-03-18 2025-06-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis
CN116832040A (zh) * 2023-06-12 2023-10-03 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025031474A1 (en) * 2023-08-10 2025-02-13 Insilico Medicine Ip Limited Method and medicament for treating endometriosis
WO2025111752A1 (zh) * 2023-11-27 2025-06-05 中山大学 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途
WO2025170008A1 (ja) * 2024-02-07 2025-08-14 国立大学法人京都大学 成熟心筋細胞の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110198A2 (en) * 2013-01-10 2014-07-17 Zisman Lawrence S Therapeutic indications of kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
AU1364701A (en) * 1999-11-12 2001-06-06 Advanced Research And Technology Institute, Inc. Methods to detect agents useful to inhibit neurofibromatosis type 1 (nf1)
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CN101056539B (zh) * 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
CA2614959A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US20070123539A1 (en) * 2005-10-20 2007-05-31 University Of South Florida Treatment of Restenosis and Stenosis with Dasatinib
GB0609962D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CN103463621B (zh) * 2006-10-31 2016-01-06 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2359813A1 (en) * 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110198A2 (en) * 2013-01-10 2014-07-17 Zisman Lawrence S Therapeutic indications of kinase inhibitors

Also Published As

Publication number Publication date
WO2016123086A1 (en) 2016-08-04
CN107530298A (zh) 2018-01-02
US20180271864A1 (en) 2018-09-27
EP3250192A4 (en) 2018-09-26
JP2018504416A (ja) 2018-02-15
US20250360129A1 (en) 2025-11-27
MX2022012505A (es) 2022-11-07
MX2017009643A (es) 2018-05-04
EP4653015A2 (en) 2025-11-26
HK1245678A1 (zh) 2018-08-31
JP6854766B2 (ja) 2021-04-07
CN107530298B (zh) 2021-06-04
US20200009142A1 (en) 2020-01-09
EP3250192B1 (en) 2025-10-08
JP2025061369A (ja) 2025-04-10
US11458137B2 (en) 2022-10-04
US20230036788A1 (en) 2023-02-02
EP3250192A1 (en) 2017-12-06
JP2023052878A (ja) 2023-04-12
JP2021050218A (ja) 2021-04-01
US10471059B2 (en) 2019-11-12
CA2974958A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Zhao et al. An essential role for Wnt/β-catenin signaling in mediating hypertensive heart disease
Li et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy
Song et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis
JP7461071B2 (ja) クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
US20110244059A1 (en) Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
Wu et al. Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene
JP7570100B2 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
Choi et al. Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival
Schramm et al. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling
Xu et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 b/b-catenin signaling in neonatal rats
Wei et al. Tert promotes cardiac regenerative repair after MI through alleviating ROS-induced DNA damage response in cardiomyocyte
JP2025041721A (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
HK40057503A (en) Compositions and methods of using tyrosine kinase inhibitors
EP3393477A1 (en) Combination of a cardiac steroid and an akt inhibitor for the treatment of cardiovascular diseases and disorders
CA2974958C (en) Compositions and methods of using tyrosine kinase inhibitors
O'Neill IV et al. Germline deletion of FAK-related non-kinase delays post-natal cardiomyocyte mitotic arrest
CA3247585A1 (en) TREATMENT OF MUSCLE FIBROSIS
Song et al. FOXM1 Protects Against Myocardial Ischemia‐Reperfusion Injury in Rodent and Porcine Models by Suppressing MKRN1‐Dependent LKB1 Ubiquitination
US20250134889A1 (en) Targeting ire1 kinase and fmrp for prophylaxis, management and treatment of atherosclerosis
Wang et al. Kielin/chordin-like protein (KCP) deficiency exacerbates doxorubicin-induced myocardial injury by promoting macrophage M1 polarization through autophagy inhibition.
Haufe The role of transient fetal hypoxia in the development of pulmonary hypertension dependent on p22phox
JP2007529540A (ja) 混合系統キナーゼの阻害およびそのための用途
Editors Circulation Editors’ Picks: Most Read Articles on Studies Performed in an Animal Model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057503

Country of ref document: HK